

AMENDMENTS TO THE CLAIMS

Claims 1-50 (Cancelled).

Claim 51 (Currently amended): A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of an isolated or recombinantly expressed polypeptide comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3), wherein the immune-mediated damage is caused by lymphocytes, NK cells or NK-like cells.

Claims 52-59 (Cancelled)

Claim 60 (Currently amended): A method for protecting cells, organs or tissues comprising exposing said cells, organs or tissues to an immunoprotective amount of an isolated or recombinantly expressed polypeptide ~~that contains at least one comprising a sequence~~ selected from the group consisting of ~~AX₁X₂X₃AX₄X₅X₆R (SEQ ID NO:1), AX₁LSAEX₅X₆R (SEQ ID NO:1), AX₁X₂X₃A (SEQ ID NO:1)~~ the HSP47 polypeptide sequence presented as SEQ ID NO:6, and the amino acid sequence AVLSAEQLR (SEQ ID NO:3), wherein said polypeptide is effective to prevent damage caused by lymphocytes, NK cells or NK-like cells, wherein X₁ is V, L, A, or T, X₂ is L or H, X₃ is S or V, X₄ is D or E, X₅ is Q, K, or R, and X₆ is L or V (SEQ ID NO:1), and wherein X₁, X₂ and X₃ are any amino acid when the polypeptide contains the sequence AX₁X₂X₃AEQLR (SEQ ID NO: 29).

Claim 61 (Currently amended): The method of claim 60, wherein said polypeptide ~~comprises the sequence AX₁X₂X₃AX₄X₅X₆R, wherein X₁ is V, L, A or T, X₂ is L or H, X₃ is S or V, X₄ is D or E, X₅ is Q, K or R, and X₆ is L or V (SEQ ID NO: 1)~~ is the HSP47 polypeptide sequence presented as SEQ ID NO:6.

Claim 62 (Currently amended): The method of claim ~~60~~ 61, wherein said polypeptide comprises ~~the~~ a sequence AX₁LSAEX₅X₆R wherein X₁ is V, L, or T, X₅ is Q, K, or R, and X₆ is L or V (SEQ ID NO:11) having at least 95% sequence identity to SEQ ID NO:6 and said polypeptide exhibits immunoprotective properties of (SEQ ID NO:6).

Claim 63 (Currently amended): The method of claim ~~60~~ 61, wherein said polypeptide comprises ~~the~~ a sequence AX₁X₂X₃AEQLR, wherein X₁, X₂, and X₃ are any amino acid (SEQ ID NO:29) having at

least 90% sequence identity to SEQ ID NO:6 and said polypeptide exhibits immunoprotective properties of SEQ ID NO:6).

Claim 64 (Currently amended): The method of claim ~~60-61~~, wherein said polypeptide comprises a sequence X₁ is V or A, X₂ is L or H, and X₃ is preferably S or V (SEQ ID NO:2) having at least 80% sequence identity to SEQ ID NO:6 and said polypeptide exhibits immunoprotective properties of (SEQ ID NO:6).

Claim 65 (Currently amended): The method of ~~60~~61, wherein said polypeptide comprises ~~the a~~ sequence ~~AVLSAX₄X₅LR wherein X₄ is D or E, and X₅ is K or Q (SEQ ID NO:13)~~ having at least 90% sequence identity to SEQ ID NO:6 and said polypeptide exhibits immunoprotective properties of (SEQ ID NO:6).

Claim 66 (Currently amended): A method for protecting cells, organs or tissues comprising exposing said cells, organs or tissues to an immunoprotective amount of an isolated or recombinantly expressed Hsp47 polypeptide comprising the sequence AVLSAEQLR (SEQ ID NO:3), to prevent damage caused by lymphocytes, NK cells or NK-like cells.

Claim 67 (Currently amended): The method of claim 66, wherein said Hsp47 polypeptide ~~comprises the sequence~~ has at least 80% sequence identity to HSP47 (SEQ ID NO:6), AVLSAEQLR (SEQ ID NO:3) and said polypeptide exhibits immunoprotective properties of (SEQ ID NO:6).

Claim 68 (Previously Presented): The method of claim 66, wherein said Hsp47 polypeptide consists essentially of the sequence AVLSAEQLR (SEQ ID NO:3).

Claim 69-73 (Cancelled).

Claim 74 (Currently amended): The method of claim 66, wherein said Hsp47 polypeptide ~~comprises a sequence at least 55.5% identical~~ has at least 90% sequence identity to SEQ ID NO:6, 3 and said polypeptide exhibits immunoprotective properties of (SEQ ID NO:6).

Claim 75 (Currently amended): The method of claim 66, wherein said Hsp47 polypeptide ~~comprises a sequence at least 66.6% identical to SEQ ID NO:3~~ has at least 95% sequence identity of SEQ ID NO:6, and said polypeptide exhibits immunoprotective properties of (SEQ ID NO:6).

Claims 76-292 (Canceled).

Claim 293 (New): The method of any one of claims 60, 61-68, 74, and 75, wherein said polypeptide is a recombinantly expressed polypeptide.